title: Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.
abstract: Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.
authors.affiliation: Department of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USA.
authors.forename: Han
authors.initials: H
authors.lastname: Lei
authors.affiliation: Department of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USA.
authors.forename: Sha
authors.initials: S
authors.lastname: Jin
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Erik
authors.initials: E
authors.lastname: Karlsson
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Stacey
authors.initials: S
authors.lastname: Schultz-Cherry
authors.affiliation: Department of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USA.
authors.forename: Kaiming
authors.identifier: 0000-0001-7736-9875
authors.initials: K
authors.lastname: Ye
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000954:Antigens, Surface / Q000276:immunology; D061505:Cell Surface Display Techniques; D003429:Cross Reactions; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000097:blood; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics / Q000235:genetics* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D008168:Lung / Q000276:immunology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D012441:Saccharomyces cerevisiae / Q000235:genetics*; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000954:Antigens, Surface; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D011994:Recombinant Proteins